South Korean biopharmaceutical company developing first-in-class small-molecule therapeutics for immune diseases
South Korean biopharmaceutical company developing first-in-class small-molecule therapeutics for immune diseases. Its proprietary protein-protein interaction inhibitor discovery platform uses target-protein structure-based medicinal chemistry to identify compounds that regulate immune signaling, with focus areas including asthma, atopic dermatitis, allergies, and COPD.